Journal of Comparative Effectiveness Research

Article	Citations
Cost–effectiveness of pembrolizumab for second-line treatment of esophageal squamous cell carcinoma patients with a combined positive score of 10 or more	151
Acute effects of resistance exercise with blood flow restriction on cardiovascular response: a meta-analysis	43
Long-term effectiveness and safety of ravulizumab in paroxysmal nocturnal hemoglobinuria: a plain language summary	41
Engaging veterans in the research process: a practical guide	31
Effect of home-based exercise programs with e-devices on falls among community-dwelling older adults: a meta-analysis	29
Journal of Comparative Effectiveness Research : 2022 year in review	25
Economic burden of sickle cell disease in the United States: a retrospective analysis of a commercial insurance database	23
Smart connected insulin dose monitoring technologies versus standard of care: a Canadian cost–effectiveness analysis	22
Postoperative outcomes and anesthesia type in total knee arthroplasty in patients with obstructive sleep apnea	22
An observational cohort study of pelvic floor photobiomodulation for treatment of chronic pelvic pain	21
Atezolizumab with chemotherapy in first-line treatment for metastatic urothelial cancer: a cost–effectiveness analysis	20
Corrigendum	20
MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy	20
Effectiveness and safety of asfotase alfa for people with hypophosphatasia: a plain language summary of three studies	19
Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-naïve people with HIV-1: a systematic literature review and network meta-analysis	19
Discharges against medical advice and 30-day healthcare costs: an analysis of commercially insured adults	17
Costs associated with nonalcoholic steatohepatitis disease progression in Medicare patients: a retrospective cohort study	17
Impact of clinical research coordinators on research output in orthopedic surgery	16
Cost–effectiveness analysis of a resource-intensive approach versus minimally invasive strategy for high-risk transcatheter aortic valve replacement patients	16
Bayesian hierarchical model-based network meta-analysis to overcome survival extrapolation challenges caused by data immaturity	14
Impact of surgical complications on hospital costs and revenues: retrospective database study of Medicare claims	14
Letter in reply	14
The cost–effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USA	14
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 20	14
Cost of disease progression among US patients with human epidermal growth factor receptor 2-positive metastatic breast cancer	13

Lessons on the use of real-world data in medical device research: findings from the National Evaluation System for Health Technology Test-Cases	12
Ravulizumab in adults and children with atypical hemolytic uremic syndrome: a plain language summary of three studies	12
Clinical assessment of the potential use of a novel single-dose prefilled injection device for the administration of Acthar Gel in children: a narrative review	12
Cost–effectiveness analysis of prolonged-release fampridine to treat walking disability of multiple sclerosis in China	11
Time-limited reimbursement and Temporary Access Process for early access to oncology treatments in Canada: a perspective based on the epcoritamab experience	11
Real-world ePRO use and clinical outcomes using electronic patient-reported symptom monitoring for patients with advanced non-small-cell lung cancer receiving first-line pembrolizumab	11
EU HTA Joint Clinical Assessment: are patients with rare disease going to lose out?	11
A real-world analysis of antidepressant medications in US veterans aged 60 years and older: a comparative analysis	11
Clinical manifestations and healthcare utilization before diagnosis of transthyretin amyloidosis	11
Healthcare utilization and costs following molecular diagnostic testing among patients with vaginitis	11
Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type 2 diabetes in Canada	10
R WE ready for reimbursement? A round up of developments in real-world evidence relating to HTA: part 3	10
Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema	10
Cost–effectiveness of lung cancer screening with volume computed tomography in Portugal	10
Augmenting external control arms using Bayesian borrowing: a case study in first-line non-small cell lung cancer	10
Corrigendum	10
Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients	10
Healthcare costs and resource utilization of patients with chronic post-traumatic stress disorder: a retrospective US claims analysis of commercially insured patients	10
How the use of standardized protocols may paradoxically worsen disparities for safety-net hospitals	9
Cost–utility analysis of single nucleotide polymorphism panel-based machine learning algorithm to predict risk of opioid use disorder	9
Increasing transparency in indirect treatment comparisons: is selecting effect modifiers the missing part of the puzzle? A review of methodological approaches and critical considerations	9
Comparison of intravenous versus topical tranexamic acid in primary total hip arthroplasty: a systematic review and meta-analysis of ten randomized trials	9
Real-world weight changes in people with HIV-1 at risk of weight gain (female, Black or Hispanic) switching from integrase strand transfer inhibitors	9
Review and estimation of disutility for joint health states of severe and nonsevere hypoglycemic events in diabetes	9
To replicate or not to replicate? Insights and interpretations from a randomized trial duplication initiative	9
The triple win – implementation science benefits patients, healthcare systems and industry alike	9
Dependent censoring bias assessment using inverse probability of censoring weights: Type 2 diabetes mellitus risk in patients initiating bisoprolol versus other antihypertensives in a Clinical Practic	8
Characterization of medical device randomized controlled trials with adaptive designs	8
Impact analysis of expanding narrow-spectrum antibiotic use for children with ear, sinus and throat infections	8
Effectiveness of tisagenlecleucel versus real-world standard of care in relapsed/refractory follicular lymphoma	8
Diversity in clinical trial inclusion for peripheral artery disease lower extremity endovascular interventions: a systematic review protocol	8
Letter to the editor: network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema	8
Healthcare resource utilization and costs in pediatric pulmonary arterial hypertension in a third-level hospital in Mexico	8
Impact of COVID-19 on chronic pain structures: data from French national survey	8
Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol	8
Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer	8
Comparison of Enterprise stent 2 with 1 in assisting coiling of ruptured aneurysms: a real-world study	8
The effects of Pilates on pain, functionality, quality of life, flexibility and endurance in lumbar disc herniation	8
Ravulizumab for adults with generalized myasthenia gravis: a plain language summary of three studies	8
Are indirect comparisons for treatments in migraine necessitas? Many inevitable challenges to overcome	7
Tr14 gel for the treatment of acute ankle sprains: a plain language summary of the TRAUMED trial	7
Comparative effectiveness research in COVID-19 using real-world data: methodological considerations	7
Cost–effectiveness of empagliflozin versus weekly semaglutide as add-on therapy for Type 2 diabetes	7
COVID-19 clinical trials: who is likely to participate and why?	7
Rivaroxaban versus low-molecular-weight heparins for short- and long-term prognosis in patients with deep vein thrombosis after spontaneous intracranial hemorrhage	7
Does off-hours endoscopic hemostasis affect outcomes of nonvariceal upper gastrointestinal bleeding?	7
Navigating adalimumab biosimilars: an expert opinion	7
Overall survival in the UK in mycosis fungoides or Sézary syndrome cutaneous T-cell lymphoma: comparative effectiveness of mogamulizumab versus current standard of care	7
Access in all areas? A round up of developments in market access and health technology assessment: part 1	7
Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in colorectal cancer: a meta-analysis	7

An impact evaluation of an education bundle for patients at risk of developing venous thromboembolism	7
Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma	6
Once-nightly sodium oxybate (FT218) improved symptoms of disrupted nighttime sleep in people with narcolepsy: a plain language summary	6
Treatment goals for rheumatoid arthritis: patient engagement and goal collection	6
Cost–effectiveness of ensartinib for patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer in China	6
A systematic review of discounting in national health economic evaluation guidelines: healthcare value implications	6
Corrigendum	6
Quantitative bias analysis for external control arms using real-world data in clinical trials: a primer for clinical researchers	6
An evaluation of stakeholder engagement in comparative effectiveness research: lessons learned from SWOG S1415CD	6
A value-based budget impact model for dronedarone compared with other rhythm control strategies	6
An economic evaluation of teledermatology care delivery for chronic skin diseases	6
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 10	6
Quality in qualitative evidence: new best practice principles from NICE’s real-world evidence framework	6
Expanding the learning health system model to be health literate	6
The impact of lower limb chronic venous disease on quality of life: patient and physician perspectives	6
Use of transportability methods for real-world evidence generation: a review of current applications	6
Burden of illness for patients with primary biliary cholangitis: an observational study of clinical characteristics and healthcare resource utilization	6
Mapping methods gaps between EU joint clinical assessments and local health technology assessment decision-making: an environmental scan of guidance in select EU markets and harmonization challenges	5
Application of quantitative bias analysis for unmeasured confounding in cost–effectiveness modelling	5
A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib	5
QDOT MICRO™ versus THERMOCOOL ® SMARTTOUCH™ and THERMOCOOL SMARTTOUCH ® Surround Flow in radiofrequency ablation of paroxysmal atr	5
Structural hemodynamic valve deterioration durability of RESILIA-tissue versus contemporary aortic bioprostheses	5
Assessing the change in disease severity based on depressive symptoms in real-world psoriasis patients	5
In-hospital mortality in amyloid light chain amyloidosis: analysis of the Premier Healthcare Database	5
Expert perspectives on the use of safinamide for Parkinson’s disease in Portugal: insights from a Portuguese Delphi Consensus	5
Navigating the unknown: how to best ‘reflect’ standard of care in indications without a dedicated treatment pathway in health technology assessment submissions	5
Clinical and economic burden among older adults with acromegaly in the United States	5
Evaluating real-world COVID-19 vaccine effectiveness using a test-negative case–control design	5
Economic impact of reduced postoperative visits after inflatable penile prosthesis implantation	5
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 15	5
Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US	5
Letter in Reply: indirect comparison of quality-of-life scores between patients with advanced breast cancer receiving palbociclib and abemaciclib in combination with fulvestrant	5
Impact of the COVID-19 pandemic on healthcare resource utilization across selected disease areas in the USA	4
The need to consider market access for pharmaceutical investment decisions: a primer	4
Val (EU) xit: do we need an international ISPOR value flower?	4
Visualizing the target estimand in comparative effectiveness studies with multiple treatments	4
Clinical and economic implications of focal dissection treatment following percutaneous transluminal angioplasty of the superficial femoral artery: an exploratory analysis based on the TOBA II Study	4
Impact analysis of expanded access to ketamine for treatment-resistant depression	4
Evaluation of the treatment patterns among commercially insured patients with nonvalvular atrial fibrillation prescribed an oral anticoagulant by race/ethnicity	4
COVID-19 complications in males and females: recent developments	4
Safety and effectiveness of intranasal esketamine for treatment-resistant depression: a real-world retrospective study	4
Robotic-assisted total hip arthroplasty: an economic analysis	4
Economic burden of lives lost due to COVID-19 in California State	4
An international observational study assessing conservative management in hemorrhoidal disease: results of CHORALIS (aCute HemORrhoidal disease evALuation International Study)	4
A review of stakeholder recommendations for defining fit-for-purpose real-world evidence algorithms	4
Comparing the efficacy of cipaglucosidase alfa plus miglustat with other enzyme replacement therapies for late-onset Pompe disease: a network meta-analysis utilizing patient-level and aggregate data	4
Why, whether and how to use high-flow nasal therapy in acute exacerbations of chronic obstructive pulmonary disease	4
Economic burden of early-stage non-small-cell lung cancer: an assessment of healthcare resource utilization and medical costs	4
Semaglutide treatment for obesity in teenagers: a plain language summary of the STEP TEENS research study	4
Steroid switching in dystrophinopathy treatment: a US chart review of patient characteristics and clinical outcomes	4
Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data	4
Impact of comparative effectiveness research on Medicare coverage of direct oral anticoagulants	4
Budesonide/formoterol versus salmeterol/fluticasone for asthma in children: an effectiveness and safety analysis	4
Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting	4
Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis	4
Budget impact analyses of hemoglobin A1c and lipid panel point-of-care testing with Afinion™ 2 in Canada and Italy	4
Evaluation of inpatient and emergency department healthcare resource utilization and costs pre- and post-nusinersen for the treatment of spinal muscular atrophy using United States claims	4
Cost–effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma	4
Resource utilization and economic outcomes following repetitive transcranial magnetic stimulation for treatment-resistant depression: a retrospective observational analysis	4
How pharma can amplify product value with implementation science	4
Respiratory and nonrespiratory COVID-19 complications in patients with obesity: recent developments	4
R WE ready for reimbursement? A round up of developments in RWE relating to health technology assessment: part 2	4
Vaginal laser therapy for gynecologic conditions: re-examining the controversy and where do we go from here	4
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 4	4
Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data inROS1+ NSCLC	4
Comparing the performance of two-stage residual inclusion methods when using physician's prescribing preference as an instrumental variable: unmeasured confounding and noncollapsibility	3
Cost–effectiveness of concurrent radiation with cetuximab or chemotherapy in older patients with oropharyngeal cancer	3
Network meta-analysis of multiple doses of vonoprazan for the treatment of erosive esophagitis	3
A process to validate prognostic factors for unanchored matching-adjusted indirect comparison of single-arm trials in oncology: a proof-of-concept study	3
Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema	3
The effects of exercises with a Pilates ball on balance, reaction time and dual-task performance of kindergarten children	3
Potential policy reforms to strengthen the accelerated approval pathway	3
Systematic literature review of evidence in amyloid light-chain amyloidosis	3
Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis	3
Guidance on using real-world evidence from Western Europe in Central and Eastern European health policy decision making	3
Plain language summary of safety and symptom improvement with vibegron in people with overactive bladder: results from the EMPOWUR study	3
Use of interrupted time-series analyses in evaluating health economic outcomes following implementation of multilayer water-tight wound closure in a primary total joint arthroplasty population	3
Economic burden of complicated ureteral stent removal in patients with kidney stone disease in the USA	3
A real world cost-minimization analysis comparing the use of different endoscopic staplers in video-assisted thoracic surgery lobectomy procedures	3
Six-minute walk test as clinical end point in cardiomyopathy clinical trials, including ATTR-CM: a systematic literature review	3

Corrigendum	3
PEG hydrogel sealant versus fibrin glue in posterior fossa surgery: an economic comparison across five European countries	3
Comparing the outcomes and costs of cardiac monitoring with implantable loop recorders and mobile cardiac outpatient telemetry following stroke using real-world evidence	3
Patient characteristics, healthcare resource utilization and costs across treatment lines in diffuse large B-cell lymphoma – a German claims data study	3
Missing data methods for intensive care unit SOFA scores in electronic health records studies: results from a Monte Carlo simulation	3
Gastrointestinal adverse effects associated with the use of intravenous oliceridine compared with intravenous hydromorphone or fentanyl in acute pain management utilizing adjusted indirect treatment c	3
Access in all areas? a round up of developments in market access and health technology assessment: part 4	3
Letter to the Editor: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus	3
Changes in symptom burden and quality of life among women with uterine fibroids receiving relugolix combination therapy: a plain language summary	3
Promoting community stakeholder engagement in research on treatment for pregnant women with opioid use disorder	3
Evaluation of emerging NASH therapies: the impact of treatment efficacy profiles on long-term health outcomes	3
The cost–effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark	3
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 19	3
Screening for diminished ovarian reserve in Portugal: a cost-saving answer to shorten the fertility journey	3
Cost–effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain	3
A protocol for three observational cohort studies evaluating adverse outcomes, excess costs and repeat procedures after surgery for breast cancer in the USA	3
Outcomes of patients with nonmetastatic gastric adenocarcinoma according to perioperative treatment strategy: a real-world, population-based study	3
Meta-analysis of visual pretreatment for the prevention of emergence delirium in children undergoing ophthalmic surgery	3
Matching-adjusted indirect comparisons of efficacy outcomes between etrasimod and ozanimod for moderately to severely active ulcerative colitis	3
Clinical outcomes of retrievable inferior vena cava filters for venous thromboembolic diseases	3
Evaluation of hypercholesterolemia management in at-risk patients by cardiologists in France: a case vignette-based study	3
Letter in reply: network meta-analysis for indirect comparison of lanadelumab and for the treatment of hereditary angioedema	3
Prognostic and predictive value of microsatellite instability status among patients with colorectal cancer	3
Cost impact of Bruton’s tyrosine kinase inhibitor selection in Medicare patients with chronic lymphocytic leukemia	3
Distinguishing cardiac catheter ablation energy modalities by applying natural language processing to electronic health records	3
A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer	3
Access in all areas? A roundup of developments in market access and health technology assessment: part 6	3
Sex-based differences in the outcomes of patients with lung carcinoids	3
Are eSports more than just sitting? A study comparing energy expenditure	3
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 18	3
Factors impacting chronic disease medication adherence in the UAE: a prospective cohort study, 2021–2022	3
A clinical decision support tool for metabolic dysfunction-associated steatohepatitis in real-world clinical settings: a mixed-method implementation research study protocol	3
Cost–effectiveness and cost-benefit analysis of oliceridine in the treatment of acute pain	3
Novel and existing flexible survival methods for network meta-analyses	3
Matching-adjusted indirect comparison via a polynomial-based non-linear optimization method	3
The views of teenagers with obesity, their caregivers, and doctors: a plain language summary of the ACTION Teens global survey	3
A US national update of health condition prevalence among privately-insured autistic adults	3
Healthcare utilization and costs among patients with acromegaly in the United States	3
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 17	3
Healthcare resource utilization among nursing home residents with Parkinson's disease psychosis: an analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics	2
Trends in adoption of knotless tissue control devices in robotic surgery	2
Acceptability and consumers' willingness to pay for comprehensive medication management services in Brazil	2
Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas that can't be removed by surgery, and impact on how the condition affects caregivers: a plain language summary	2
R WE ready for reimbursement? A round up of developments in real-world evidence relating to HTA: part 5	2
Impact analysis of expanding anti-TNF therapy for Crohn’s disease	2
Impact of perioperative chemotherapy on survival outcomes among patients with metastatic colorectal cancer to the liver	2
Corrigendum	2
Rational use of inhaled corticosteroids for the treatment of COPD: a plain language summary	2
Why is target trial emulation not being used in health technology assessment real-world data submissions?	2
Risk of long-term care admissions among Medicare beneficiaries treated with pimavanserin or quetiapine for Parkinson's disease psychosis in USA: a retrospective administrative claims database analysis	2
The burden of Alagille syndrome: uncovering the potential of emerging therapeutics – a comprehensive systematic literature review	2
Real-world evidence: a practical toolbox for collecting health state utilities	2
Meta-analyses of deflazacort versus prednisone/prednisolone in patients with nonsense mutation Duchenne muscular dystrophy	2
Evaluation of reporting in time-driven activity-based costing studies on cardiovascular diseases: a scoping review	2
Elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma: an updated matching-adjusted indirect comparison	2
A matching-adjusted indirect comparison of centanafadine versus lisdexamfetamine, methylphenidate and atomoxetine in adults with attention-deficit/hyperactivity disorder: long-term safety and efficacy	2
Corrigendum	2
Digital variance angiography in patients undergoing lower limb arterial recanalization: cost–effectiveness analysis within the English healthcare setting	2
Design and methods of a tailored approach for diabetes prevention in women with previous gestational diabetes	2
Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus	2
The cost–effectiveness, of pegcetacoplan compared with ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria, in a UK setting	2
Cost–effectiveness analysis of Avance ® allograft for the treatment of peripheral nerve injuries in the USA	2
Real-world studies of crizotinib in patients with ROS1-positive non-small-cell lung cancer: experience from China	2
Assessing the performance of physician's prescribing preference as an instrumental variable in comparative effectiveness research with moderate and small sample sizes: a simulation study	2
Flexibility in assessment of rare disease technologies via NICE's single technology appraisal route: a thematic analysis	2
Real-world economic and clinical outcomes associated with current hemostatic matrix use in spinal surgery	2
A real-world, population-based study for the outcomes of patients with metastatic colorectal cancer to the liver with distant lymph node metastases treated with metastasectomy	2
Improved estimation of overall survival and progression-free survival for state transition modeling	2
Bridging the gap between oncology clinical trials and real-world data: evidence on replicability of efficacy results using German claims data	2
Breast-conserving surgery versus mastectomy for older women with triple-negative breast cancer: population-based study	2
Evaluating patients' satisfaction and preferences with a secondary prevention cardiovascular polypill: the Aurora Study	2
Effects of 12-week Pilates training program on cardiac autonomic modulation: a randomized controlled clinical trial	2
Indirect treatment comparison of lanadelumab and a C1-esterase inhibitor in pediatric patients with hereditary angioedema	2
Transportability of nonlocal real-world evidence and its relevance to health technology assessment: a primer	2
The use of nonrandomized evidence to estimate treatment effects in health technology assessment	2
The economic impact of stent retriever selection for acute ischemic stroke: a cost analysis of MASTRO I from the healthcare system perspective of the United States, Canada and eight European countries	2
Evaluating the robustness of an AI pathfinder application on eligibility criteria in multiple myeloma trials using real-world data and historical trials	2
Implementation of electronic patient-reported outcomes for symptom monitoring during cancer treatment: the importance of getting it right	2
A novel injection device to administer repository corticotropin injection for inflammatory disease treatment: findings from a market research study	2
Phosphodiesterase type 5 inhibitors as treatment for erectile dysfunction: a webinar-based poll unveiling perceptions of healthcare professionals	2
Cost standard set program: moving forward to standardization of cost assessment based on clinical condition	2